Twist Bioscience Corporation (TWST)
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript
Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript
Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made
Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.
Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.66 per share a year ago.
Twist Bioscience Corporation (TWST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Twist Bioscience Corporation (TWST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Twist Bioscience (NASDAQ:TWST) Shares Gap Down – What’s Next?
Shares of Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $52.49, but opened at $49.90. Twist Bioscience shares last traded at $49.73, with a volume of 213,406 shares. Analyst Ratings Changes A number of brokerages have issued reports on TWST. TD
Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases
Twist Bioscience Corporation reported Q1 2026 revenue of $103.7M, up 17% YoY, and raised full-year guidance to $435–$440M. TWST targets adjusted EBITDA breakeven in Q4 2026, with gross margin expected above 52% for fiscal 2026. The company's DNA synthesis platform and AI-driven growth are promising, but profitability and market size remain concerns.
Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.53 per share a year ago.
Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know
Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
